| Jun 7 |
Halozyme Therapeutics Scores RS Rating Jump To 91
|
| Jun 7 |
Halozyme Therapeutics: The Story Brightens
|
| Jun 7 |
Halozyme downgraded at Piper Sandler despite guidance raise
|
| Jun 7 |
Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%
|
| Jun 6 |
Halozyme hits 52-week high as patent win prompts guidance raise
|
| Jun 6 |
Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue?
|
| Jun 6 |
Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU
|
| Jun 6 |
Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
|
| Jun 5 |
Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
|
| Jun 4 |
Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
|
